Document is current

Article History

Received: 23 August 2024

Accepted: 31 October 2024

First Online: 11 February 2025

Declarations

:

: J. Furukawa has received honoraria for lectures from Merck, MSD, and Ono. T. Kato has received honoraria for lectures from MSD. T. Yamasaki and K. Monji have nothing to disclose. T. Tanaka has received honoraria for lectures from Takeda Pharmaceutical. N. Tsuchiya has received research funding from Eisai, Novartis, and Pfizer; and has received honoraria for lectures from Astellas Pharma, Merck, and Pfizer. T. Miyagawa, H. Yaegashi, T. Sano, and T. Karashima have nothing to disclose. K. Fujita has received honoraria for lectures from Bristol Myers Squibb Japan, Janssen Pharmaceutical, and Ono Pharmaceutical. J. Hori has nothing to disclose. T. Ito and M. Kajita report employment with Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA. Y. Tomita has participated in consulting or advisory roles for Eisai, MSD, and Ono Pharmaceutical; has received honoraria from Astellas Pharma, Bristol Myers Squibb Japan, Chugai Pharma, Novartis, Ono Pharmaceutical, and Pfizer; and has received research funding from Astellas Pharma, AstraZeneca, Chugai Pharma, Eisai, MSD, Novartis, Ono Pharmaceutical, Pfizer, and Takeda. N. Shinohara has received grants or contracts from Bristol Myers Squibb, Ono Yakuhin, and Takeda; has received honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Bristol Myers Squibb, MSD, Novartis, Ono Yakuhin, Pfizer, and Takeda; and is the president of the Japanese Society of Renal Cancer. M. Eto has received research funding from Bristol Myers Squibb, MSD, Ono Pharmaceutical, and Takeda Pharmaceutical; and has received honoraria for lectures from Astellas Pharma, AstraZeneca, Bayer Yakuhin, Bristol Myers Squibb, Eisai, Janssen Pharmaceutical, Merck, MSD, Ono Pharmaceutical, Pfizer, and Takeda Pharmaceutical. M. Oya has received honoraria from Bayer, Bristol Myers Squibb, Eisai, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Merck & Co., Kenilworth, NJ, Ono, Pfizer, and Takeda; and has received scholarship endowments from Bayer, Eisai, and Takeda. H. Uemura has received research grants from Astellas Pharma, AstraZeneca, Janssen, Ono Pharmaceutical, Taiho, and Takeda; has received consulting fees from Ono Pharmaceutical and Sanofi; has received payment or honoraria for lectures and speakers’ bureaus from Bayer, Janssen, MSD, Pfizer, Sanofi, and Takeda; and has received payment for expert advisory testimony from AstraZeneca, Ono Pharmaceutical, and Sanofi.